Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477 is registered in ClinicalTrials.gov with Reistone Biopharma Company Limited as lead sponsor.

NCT NCT03675477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03675477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.
Lead sponsor
Reistone Biopharma Company Limited
Phase
Phase 2
Overall status
Completed
Start date
April 13, 2019
Completion date
February 3, 2021
Enrollment
164 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis